Clinical Trial of Simvastatin to Treat Generalized Vitiligo
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The investigators purpose is to initiate a phase II, randomized, placebo-controlled clinical
trial to test simvastatin, an FDA-approved medication for hypercholesterolemia, as a new
treatment for vitiligo. The aims of this placebo-controlled study seek to determine the
safety and potential efficacy of simvastatin 80mg daily versus placebo in adult male patients
with generalized vitiligo. Additionally, the investigators will collect blood to examine the
effect of simvastatin on autoreactive CD8+ T cells in vitiligo patients.
Phase:
Phase 2
Details
Lead Sponsor:
John Harris University of Massachusetts, Worcester